Nebulised bronchodilators are a mainstay of acute COPD exacerbation treatment. No clinical studies assessing the clinical response to bronchodilators delivered by varying nebuliser devices exist.
Introduction
Nebulised bronchodilators are a mainstay of acute COPD exacerbation treatment. No clinical studies assessing the clinical response to bronchodilators delivered by varying nebuliser devices exist.
Aim
To assess the clinical efficacy of the vibrating mesh (VM) nebuliser (Aerogen Ultra Image A) as compared to the standard oxygen-driven small volume (SV) nebuliser (Hudson micromist Image B) in a cohort of patients hospitalised with an acute exacerbation of COPD.
Conclusion
• Bronchodilator delivery by vibrating mesh nebulisers result in a significantly greater improvement in FVC and a larger volume response to bronchodilators in patients experiencing an acute exacerbation of COPD, as compared to standard small volume nebulisers. • This was accompanied by a significant decrease in symptom scores.
• We and others have previously shown that exacerbation recovery is associated with increases in respirable lung volume. Therefore there is a potential that greater bronchodilator delivery with these devices may hasten exacerbation recovery but this has yet to be explored.
Participants
• The VM nebuliser group demonstrated a greater volume response to bronchodilators with clinically significant increases in FVC(>12% and >200ml), IC(>10% of predicted) and reduction in RV (>300ml). FEV 1 increased significantly in both groups but increases did not exceed 200ml. The FEV 1 /FVC ratio was preserved.
Borg Breathless Score decreased significantly in the VM group only. There was no definite linear association between change in volume of flow response parameters and Borg score. Both groups had comparable increases in Cough Peak Flow.
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